BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ronden M, van Sörnsen de Koste J, Johnson C, Slotman B, Spoelstra F, Haasbeek C, Blom G, Bongers E, Warner A, Ward A, Palma D, Senan S. Incidence of High-Risk Radiologic Features in Patients Without Local Recurrence After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 2018;100:115-21. [DOI: 10.1016/j.ijrobp.2017.09.035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Pougnet I, Habert P, Delcourt S, Boucekine M, Wong S, Zacchariotto A, Muracciole X, Gaubert J, Padovani L. Local Recurrence Risk Score to Predict Relapse after Stereotactic Body Radiation Therapy for Lung Tumors. JCM 2022;11:6445. [DOI: 10.3390/jcm11216445] [Reference Citation Analysis]
2 Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S, Dammak S, Palma D, Ong A, Yeghiaian-Alvandi R, Buck J, Lim R. A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)03235-1. [PMID: 34879247 DOI: 10.1016/j.ijrobp.2021.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Chassagnon G, Martini K, Giraud P, Revel MP. Radiological assessment after stereotactic body radiation of lung tumours. Cancer Radiother 2020;24:379-87. [PMID: 32534799 DOI: 10.1016/j.canrad.2020.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Kim TH, Woo S, Halpenny DF, Kim YJ, Yoon SH, Suh CH. Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis. Eur J Radiol 2020;127:108978. [PMID: 32298960 DOI: 10.1016/j.ejrad.2020.108978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Yossi S, Nguyen D, Krhili S, Lizée T, Khodri M. [Prognosis factors after lung stereotactic body radiotherapy for non-small cell lung carcinoma]. Cancer Radiother 2020;24:267-74. [PMID: 32192839 DOI: 10.1016/j.canrad.2019.11.002] [Reference Citation Analysis]
6 Halpenny D, O'Dwyer E, Camacho Vasquez J, Shaverdian N, Girshman J, Ginsberg MS. Imaging of Novel Oncologic Treatments in Lung Cancer Part 2: Local Ablative Therapies. J Thorac Imaging 2020;35:37-48. [PMID: 31592831 DOI: 10.1097/RTI.0000000000000452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Munoz-schuffenegger P, Kandel S, Alibhai Z, Hope A, Bezjak A, Sun A, Simeonov A, Cho B, Giuliani M. A Prospective Study of Magnetic Resonance Imaging Assessment of Post-radiation Changes Following Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer. Clinical Oncology 2019;31:720-7. [DOI: 10.1016/j.clon.2019.05.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 Meng MB, Wang HH, Zaorsky NG, Sun BS, Zhu L, Song YC, Li FT, Dong Y, Wang JS, Chen HM, Yu XY, Yuan ZY. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer. Cancer Sci 2019;110:3553-64. [PMID: 31464032 DOI: 10.1111/cas.14185] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
9 Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-Induced Lung Injury: Assessment and Management. Chest 2019;156:150-62. [PMID: 30998908 DOI: 10.1016/j.chest.2019.03.033] [Cited by in Crossref: 176] [Cited by in F6Publishing: 190] [Article Influence: 58.7] [Reference Citation Analysis]
10 Stokes WA, Robin TP, Nath SK, Rusthoven CG. Stereotactic Body Radiation Therapy (SBRT) for Lung Metastases. Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy 2019. [DOI: 10.1007/978-3-030-16924-4_22] [Reference Citation Analysis]
11 Napel S, Mu W, Jardim-Perassi BV, Aerts HJWL, Gillies RJ. Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats. Cancer 2018;124:4633-49. [PMID: 30383900 DOI: 10.1002/cncr.31630] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 19.3] [Reference Citation Analysis]
12 Febbo JA, Gaddikeri RS, Shah PN. Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer: A Primer for Radiologists. RadioGraphics 2018;38:1312-36. [DOI: 10.1148/rg.2018170155] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
13 Dickhoff C, Rodriguez Schaap PM, Otten RHJ, Heymans MW, Heineman DJ, Dahele M. Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review. Ther Adv Med Oncol 2018;10:1758835918787989. [PMID: 30023008 DOI: 10.1177/1758835918787989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ronden MI, Palma D, Slotman BJ, Senan S. Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay. Journal of Thoracic Oncology 2018;13:855-62. [DOI: 10.1016/j.jtho.2018.02.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
15 Kalman NS, Hugo GD, Kahn JM, Zhao SS, Jan N, Mahon RN, Weiss E. Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy. Adv Radiat Oncol 2018;3:655-61. [PMID: 30370367 DOI: 10.1016/j.adro.2018.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Senan S, Rusthoven CG, Slotman BJ, Siva S. Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017. J Thorac Oncol 2018;13:488-96. [PMID: 29452269 DOI: 10.1016/j.jtho.2018.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]